wasabibarako, We have no data available from any mimotope...

wasabibarako,
We have no data available from any mimotope trials.
The keyvaxx trial that is in the planning will not have data available for a considerable while.
If the data shows the vaccines get a complete or partial response then this will add value to the share price
as the market will want to own shares in imugene with the expectation big pharma will buy out imugene
for a tidy sum.
Imugene requires good data in its trials showing the vaccines are safe and efficacious.
At present we don't have enough data and the market is very cautious in holding imugene shares as
this is high risk as are most biotechs.